DeepMed Research

THOMAS JEFFERSON UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1824-01-01

Employees: 10K

Market Cap: -

Website: http://www.jefferson.edu

Clinical Trials

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer

Early Phase 1

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Ultrasonsgraphy
Drug: Perflutren Lipid Microcpheres
Procedure: Contrast - Enhanced Ultrasound

First Posted Date: 2021-01-25

Last Posted Date: 2024-02-15

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 25

Registration Number: NCT04721886

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Phase 2

Active, not recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: Defactinib Hydrochloride
Drug: Raf/MEK Inhibitor VS-6766
Procedure: Biopsy

First Posted Date: 2021-01-22

Last Posted Date: 2023-10-10

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT04720417

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

SHAPE of Portal Hypertension in Children

Phase 2

Recruiting

Conditions: Hypertension, Portal

Interventions: Drug: SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles)
Drug: SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)

First Posted Date: 2021-01-22

Last Posted Date: 2025-02-11

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 120

Registration Number: NCT04720456

Locations: 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Blood Sample Collection for Experimental Blood Test to Track Liver Cancer

Completed

Conditions: Hepatocellular Carcinoma

First Posted Date: 2021-01-22

Last Posted Date: 2025-04-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT04720430

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Refractory Endometrial Adenocarcinoma
Refractory Endometrial Carcinoma
Refractory Endometrial Serous Adenocarcinoma
Refractory Endometrial Mixed Cell Adenocarcinoma
Refractory Endometrial Undifferentiated Carcinoma
Refractory Endometrial Clear Cell Adenocarcinoma
Refractory Endometrial Endometrioid Adenocarcinoma

Interventions: Drug: Extended-release Onapristone
Drug: Anastrozole
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Diagnostic Test: Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)
Diagnostic Test: Progesterone Receptor Positive ( PGR Positive; PR Positive)

First Posted Date: 2021-01-22

Last Posted Date: 2025-01-08

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT04719273

Locations: 🇺🇸
Jefferson Abington Hospital, Abington, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial

Not Applicable

Completed

Conditions: Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8

Interventions: Other: Tai Chi
Device: FitBit
Other: Support Group Therapy
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2021-01-20

Last Posted Date: 2025-04-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 39

Registration Number: NCT04716920

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Not Applicable

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Lung Non-Small Cell Carcinoma

Interventions: Drug: Nicotine Replacement
Drug: Bupropion Hydrochloride Controlled-release
Other: Quality of Life Assessment
Other: Best Practice
Drug: Varenicline
Other: Tobacco Cessation Counseling
Other: Questionnaire Administration

First Posted Date: 2021-01-05

Last Posted Date: 2025-03-25

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 19

Registration Number: NCT04694846

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy, Philadelphia, Pennsylvania, United States
🇺🇸
Jefferson Health, Methodist Hospital, Philadelphia, Pennsylvania, United States

A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

Not Applicable

Completed

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Other: Text Message-Based Navigation Intervention
Other: Survey Administration

First Posted Date: 2021-01-05

Last Posted Date: 2025-04-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT04694820

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Development of the Oncology Opportunity Cost Assessment Tool

Completed

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Behavioral: Focus Group
Other: Interview
Other: Research or Clinical Assessment Tool

First Posted Date: 2021-01-05

Last Posted Date: 2025-04-29

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 40

Registration Number: NCT04694911

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer

Completed

Conditions: Head and Neck Carcinoma

First Posted Date: 2020-12-14

Last Posted Date: 2025-05-15

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT04666428

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy